AEROVATE THERAPEUTICS INC (AVTE)

Company Profile

Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. The company is headquartered in Waltham, Massachusetts and currently employs 51 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, its dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (PAH), a devastating disease impacting approximately 70,000 people in the United States and Europe. Oral imatinib also demonstrated statistically significant improvement on the primary endpoint, six-minute walk distance, and multiple secondary hemodynamic endpoints in PAH patients. AV-101, delivered using a dry powder inhaler, is designed to provide lung concentrations at or above those observed with the oral dose while limiting systemic levels of the drug. PAH is an orphan disease with unmet medical needs and is characterized by high pressure in the vessels transporting blood from the right side of the heart to the lungs.

Company Info

AEROVATE THERAPEUTICS INC

930 Winter Street, Suite M-500

Waltham MASSACHUSETTS

P: 16174432400

CEO: Timothy P. Noyes

Employees: 51

Website: https://www.aerovatetx.com/